Stefan von Holtzbrinck

Altavo, a Dresden, Germany–based medical device company, raised $3.5M in a Series A2 financing led by Novalis Biotech and bm-t beteiligungsmanagement thüringen GmbH, with participation from TGFS Technologiegründerfonds Sachsen, HTGF | High-Tech Gründerfonds, TUDAG TU Dresden Aktiengesellschaft, Ostwerk, and individual private investors. Altavo is developing non-invasive silent speech technology that enables people who have lost their voice to regain natural-sounding speech. By combining advanced radar sensor technology with machine learning and AI, the platform captures subtle tongue, lip, and palate movements and converts them into real-time audible speech, offering a transformative solution for patients following laryngectomy and other severe voice impairments. The new funding will support continued company growth, clinical development, and the advancement of Altavo’s commercial product. The company is led by founders Rudolf von Buenau (CEO) and Timo Stich (CTO), alongside a leadership team that includes Lydia Allner (Clinical Affairs), Stephanie Eckert (Head of Regulatory, Clinical & QM), Dominik Eyerly (Head of Hardware Engineering), Christoph Hachmöller (Clinical Marketing), Carsten Meyer (Head of Software Engineering), and Ivana Kolar (Executive Assistant). Stay ahead of the curve in life science investments—subscribe now for the latest updates and insights: https://lnkd.in/e77bfv_e #MedicalDevice #MedTech #SeriesA #AIinHealthcare #SpeechTechnology #EuropeanBiotech 

11

1 Kommentar

#AI in #healthcare used to be a marketing play – something flashy for innovation teams to showcase at conferences and in annual reports. But as Handelsblatt reports, that era is officially over: 22 German health insurers now operate with zero reserves, and long-term care faces a projected €3.5B deficit by 2026. 👉 Now, every new solution is judged by one question: Can it cut costs? That shift may challenge hype-driven startups, but it creates a real window of opportunity for those building solutions with clear, measurable ROI, especially when they reduce friction in operations or deliver savings for high-cost indications. The focus is turning toward scalable, outcome-driven innovation: Solutions that help people live longer, healthier lives without driving up system costs. It’s no longer about who looks the most futuristic. It’s about who delivers real value – today. https://lnkd.in/eHFigFp7 #DigitalHealth #AIinHealthcare #HealthTech #ValueBasedCare #HealthcareInnovation

16

For too long, the healthcare system has focused on reactive sick care — treating illness only after symptoms appear. At ACP Healthtech and aescuvest, we’re helping change that narrative. With companies like PIUR IMAGING GmbH, we’re shifting the focus toward proactive, preventive care. Piur’s cutting-edge imaging platform equips clinicians with tools to detect diseases earlier, monitor conditions more effectively, and reduce the need for costly or invasive procedures. One of the biggest hurdles in healthcare innovation is implementation at scale. Piur has solved this by developing a vendor-independent add-on that enables any conventional ultrasound machine to perform high-resolution, tomographic 3D imaging. With our lead investment in PIUR IMAGING GmbH, we’re one step closer to this paradigm shift — bringing real-time, AI-driven health insights directly to patients. Excited to see what the coming months will bring, and hopeful to witness Frederik Bender and his team make a real impact in the preventive healthcare space.

68

5 Kommentare

Some investments remind you why venture capital exists in the first place: disruption & innovation! 💥💥💥 I’m very happy to share that Gründerfonds Ruhr participated in the €9M Seed financing round of iDEL Therapeutics GmbH, a biotech startup from Dortmund developing a new approach to cancer medicine. 🧬 iDEL is building a platform that delivers therapeutic payloads directly into the cytosol of tumor cells, with the potential to unlock previously hard-to-target cancer pathways and improve treatment outcomes for patients. Ambitious science — with the potential for real impact. Congratulations to Marcus Kostka and the entire iDEL team for reaching this milestone and for taking on one of the most important challenges in medicine. We’re proud to join a strong investor group including BiomedVC, KHAN Technology Transfer Fund and NRW.BANK. 🤝 A big thank you as well to our deal team Jan Graefe and Dr. Fabian Hogrebe for driving this investment. 👏 Moments like this are a great reminder that groundbreaking innovation is happening right here in the Ruhr region — and sometimes it has the potential to change how diseases like cancer are treated. 💥 Excited to support the journey ahead. 🤩 Thomas Raueiser Aristotelis Nastos Maria Bräutigam Thorben Bonn Jonah Eberle Marten Hausen Felix Schoernack Christian Stiebner Jan zur Hausen

54

🧘‍♀️ Germany is #DiGA soul-searching ✨ The Spitzenverband Digitale Gesundheitsversorgung annual meeting this Monday in Berlin was great. A highlight: Members of German Parliament Simone Borchardt and Matthias Mieves discussed their views on #digitalhealth innovation and DiGA regulation. Broad consensus: "There's no shortage of innovation activity in Germany", "we need to cut bureaucracy", "technology can make healthcare more inclusive", "we need DiGA regulation to ensure safety and quality for patients", "DiGAs should compete on quality." And off to the buffet we all went 🍗 I wish there had been more time for questions and debate💡 My thoughts: 🚀 The great potential of #DTx, and especially DiGA, is to improve population health at scale, with highly individualized, accessible and easy-to-use #digitaltherapeutics, clinically validated and safe. 👍 So I couldn't agree more: patients must be safe, DiGAs must compete on quality. 🔎 But does that mean government, beyond setting the regulatory framework, should seek to de facto standardize DTx by defining DiGA quality “for all” and how to measure it, enforcing it as if it were universal? 🙅 No. ❓Why then, as suggested by emerging DiGA regulation, does government appear to do just that (#AbEM Anwendungsbegleitende Erfolgsmessung)? Making it unnecessarily difficult for patients to start DiGA therapy (DiGA-#ERezept)? 🧨 In it's current form, instead of fostering individualization, accessibility, and ease of use, the regulation creates uniformity, rigidity, and lowest-common-denominator therapies. 🦘 Isn't that just what our health care system is trying to get away from? Regulatory regimes that incentivize healthcare providers to "produce for groups" rather than "producing for individuals"? 🤔 An attraction of free economies is that they give people what they want, not what a certain group thinks they ought to want. When what ought to be wanted is decided by regulators, the incentives produce an outcome that economists call "individually rational, collectively dysfunctional": individual DiGA manufacturers, incentivized to deliver on the regulatory definition of "what one ought to want", will make safe but uniform choices to produce just that. The benefit of DiGAs to society overall, measured by delivery on "what people actually want", will fall short. 🕊️ Don't we all also agree that DiGA regulation should not harm the very people it intends to protect? 🙏 My appeal to regulators: Set a regulatory framework that works for patients at scale and enforce it. Beyond that, give #doctors, #patients, and #innovators more space to do the rest. Thanks for sharing your perspectives, Simone Borchardt, Matthias Mieves and André T. Nemat. Great job Dr. Anne Sophie Geier, Diana Meskendahl (née Fischbach), Julian Milde and the #SVDGV Team. Bundesministerium für Gesundheit, Bundesministerium für Digitales und Staatsmodernisierung, Bitkom #digitalversorgt, #valuebasedcare

98

9 Kommentare

Andreessen Horowitz leads $300m Abridge AI investment 04.06.2025 - Investoren Plattform News: Trends Andreessen Horowitz is leading a $300m funding round in Abridge AI, a health tech company leveraging generative AI to automate medical transcription, in a deal that values the business at $5.3bn, according to a report by Bloomberg citing sources familiar with the matter.

1

1 Kommentar

RAYDIAX GmbH secured €7.5M to advance first-in-human studies and market entry of its CT-based therapy assistance system, TACT. The round includes €5M in venture backing from existing investors, bmp Ventures with the IBG funds and HTGF | High-Tech Gründerfonds, business angels, and new investor GETEC Family Office, alongside a €2.5M EIC Accelerator grant. 💬 “With the successful closing of our Series A1, we have reached a decisive milestone on our path toward clinical application,” said Dr. Thomas Hoffmann, CEO and Co-Founder of RAYDIAX. 🔎 Read more: https://lnkd.in/dJhfErZk #MedTech #MedicalImaging #InterventionalOncology #Funding #GSCapitalConnect

16

1 Kommentar

+++ 2.2€ mio. #investment for SpinLab startup Einklang+++ 💸 Vireo Ventures has led the funding round in Einklang, joined by SIVentures (prev. Smart Infrastructure Ventures), Saxovent Smart Eco Investments GmbH, HEIMATBOOST GmbH, Angel Invest and DnA Ventures. The #startup helps mid-sized industrial businesses reduce soaring ⚡electricity costs by combining dynamic tariffs, on-site battery storage and smart energy controls into one integrated system. Its platform automatically shifts consumption to times when solar and wind power are abundant and prices are low, stores energy when it’s cheapest, and reduces costly peak loads. ➡️The result is up to 40% cost savings, greater price stability and more energy independence. With the fresh capital, Einklang plans to scale to 100 customer sites by 2026 and further expand its battery-optimised tariff mode. Congrats Lucas Jonas, Paul Ziche, José M. Neri and Jonathan Schulte. #SmartInfrastuctureHub #EDIHSaxony

144

9 Kommentare

Press Interview, 100 Days German Hightech Agenda On the occasion of the publication of the High-Tech Agenda 100 days ago and its launch by the federal government at the end of October, BIO Deutschland e. V. held a press conference with its new CEO, Roland Sackers, on November 7 to take stock of the agenda's goals and measures. A recent flash survey showed that the mood among biotechnology companies remains stable compared to last year. A positive trend can be seen in the willingness to invest in research and development, while a rather negative trend can be seen in personnel planning. In order for the High-Tech Agenda to become a booster for the German biotech industry, federal ministries must now pool their resources and interlink them with EU initiatives, BIO Deutschland demands in the discussion. Only in this way can the measures be implemented and entrepreneurs in the industry be enabled to realize the full potential of biotechnology in Germany. The full text to the press interview can be found here: https://lnkd.in/dcihtB-W

7

World-class academic medicine cannot be built on fragmented digital foundations. Epic in Europe is not fundamentally a software discussion. It is a strategic question about how leading health systems will organize care, research, education, and innovation in the next era of medicine. Platforms such as Epic represent far more than technology implementation. They define the architecture through which institutions coordinate complexity, standardize execution, generate usable data, and build the conditions for precision medicine and responsible AI at scale. For academic medical centers, this is not simply a question of digitization. It is a strategic question about the operating model of next-generation healthcare. The ability to integrate clinical operations, scientific ambition, and organizational performance on a shared digital backbone will increasingly distinguish leading institutions from the rest. Technology on its own is insufficient. Lasting value depends on governance, standardization, clinical ownership, and the discipline to translate infrastructure into institutional capability. This is especially true for AI readiness. Advanced models are not the starting point. Trusted data, interoperable workflows, operational coherence, and accountable decision structures come first. Digital core infrastructure is no longer a support function. It is becoming a determinant of institutional excellence. Thank you to Lemonmint - Think. Act. Health. for the conversation. #DigitalTransformation #AcademicMedicine #HealthcareLeadership #HospitalStrategy #PrecisionMedicine #AIReadiness #ClinicalTransformation #HealthSystems #MedicalInnovation

62

Healthcare Technology IPO candidates for 2026: Innovaccer, HippocraticAI, Qventus, Truveta, Commure, Persivia, Tennr https://lnkd.in/ePwa2w7Z The landscape for #healthcare #technology #IPOs in #2026 is one of cautious optimism, marked by a clear evolution in investor expectations and market dynamics. The era of speculative "growth at all costs" has largely given way to a more disciplined focus on "selective scale," where profitability, proven outcomes, and robust fundamentals are paramount. #ArtificialIntelligence serves as the undeniable engine of #innovation and investment, attracting the vast majority of venture capital and driving significant #valuation premiums. Companies that have deeply embedded #AI into their core offerings, particularly for #workflow #automation, #diagnostics, and data #infrastructure, are demonstrating tangible #ROI and rapid adoption, positioning them at the forefront of the market. The maturation of #digitalhealth and #telemedicine further reinforces this trend, with successful solutions now requiring not just engagement but clear #clinical and #financial outcomes, seamless #integration with existing systems, and viable #reimbursement #pathways. In this environment, the most viable #IPO #candidates for #2026 will be late-stage private companies that have recently secured substantial #funding, demonstrate compelling financial performance (revenue growth, path to #profitability, positive cash flow), possess defensible and impactful #AI capabilities, and have a clear #strategy for navigating regulatory complexities and #cybersecurity demands. The identified companies, #Innovaccer #HippocraticAI #Qventus #Truveta #Commure #Persivia and #Tennr, exemplify these characteristics, each addressing critical pain points within the #healthcare system with scalable, #technology driven solutions. Their continued ability to execute on their growth strategies, demonstrate clear value to healthcare stakeholders, and adapt to the evolving market and #regulatory #landscape will determine their success in reaching the #public #markets. https://lnkd.in/ePwa2w7Z #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity

10

1 Kommentar